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The purpose of the study was to examine the psychometric properties of the revised Liverpool Seizure Severity Scale. The 
scale has been adapted to increase its content validity and its potential for detecting change attributable to antiepileptic drug 
treatment. Ninety-seven patients completed the revised scale of which 32 completed it for both major and minor seizures. 
Reliability of the revised scale was conducted using assessment of internal consistency and test-retest. T-tests were conducted 
to assess the ability of patients to differentiate between major and minor seizures on scores of the seizure-severity scale. 
The psychometric properties of the scale were not adversely affected by either the increase in the number of items or the 
additional response scores. Patients completing the two scales of major and minor seizures were able to reliably differentiate 
between the two. We have attempted to improve the Liverpool Seizure Severity Scale in order to enhance its reliability, 
validity and sensitivity to change. The amendments we have made have not adversely affected its psychometric properties 
and we hope that it will make it more acceptable for use in clinical trials of new antiepileptic drug treatment. The revised 
scale is currently being applied to a number of clinical trials. 
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INTRODUCTION 
In the assessment of the efficacy of treatment for 
epilepsy, seizure frequency is the commonest and of- 
ten the only end point usedl*2. A good outcome for 
an antiepileptic drug trial is reported if an individ- 
ual patient achieves a greater than 50% reduction in 
seizure frequency without any serious adverse drug 
effects, and the reported efficacy of new antiepilep- 
tic drugs is based on the number of patients who 
achieve this level. However, patients would agree that 
such a reduction, whilst worthwhile, is not necessar- 
ily satisfactory3. In the assessment of the outcome of 
surgery for patients with intractable epilepsy, a reduc- 
tion in seizure frequency is also regarded as the prin- 
cipal measure of efficacy4 and is usually determined 
by the proportion of patients becoming seizure free, 
although other variables, including social adjustment 
and psychological status, have sometimes been taken 
into accoun+. 
There are several reasons why seizure frequency 
alone is an inadequate means of assessing the efficacy 
of treatment for epilepsy, and these have been well 
documented6. In clinical trials antiepileptic drugs 
1059-1311/98/030201 + 05 $12.00/O 
may have the potential to modify the severity of a 
seizure, as perceived by the patient, without necessar- 
ily reducing the frequency. This is important, since 
previous research has demonstrated that patients’ per- 
ceptions of the severity of their seizures may be more 
important than seizure frequency in determining the 
psychosocial well being of patients with poorly con- 
trolled epilepsy’, ‘. 
While it is generally accepted that manifestations 
of seizures vary between individuals they tend to be 
stereotyped within individuals and so patients can 
classify their severity according to their own expeti- 
ence and the descriptions of their seizures given by 
regular eye witnesses. People with frequent seizures 
are also often able to differentiate between major and 
minor seizures based on a number of factors including 
whether or not they fall to the ground, the duration of 
loss of consciousness, and time taken to recover from 
the seizure and return to their normal activity. The 
advantages of a patient-based scale over a physician- 
based scale have been well documented9. A measure 
based on patients’ perception of seizure severity is 
more likely to reflect what a patient experiences dur- 
ing a seizure and may be more sensitive to subjective 
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Fig. 2: Distribution of the scores on the ictal/postictal scale. 
changes in the seizure experience which may be at- 
tributable to treatment. 
Earlier attempts to quantify seizure severity were 
based on physicians reports” and more recently have 
been developed to ask physicians to judge seizure 
severity on the basis of patients’ reports’ ’ . The Liver- 
pool Seizure Severity Scale was designed to quantify 
patients’ own perceptions of changes in seizure sever- 
ity during the course of a clinical trial of lamictal, a 
new antiepileptic drug. The development of the scale 
rested on the assumption that seizure severity is com- 
prised on two factors: patients’ perceptions of control 
over their seizures and the perceived severity of the 
ictal and postictal phenomena. In the original version 
the scale consisted of 16 items: percept of control 
subscale (percept), six items; perceived ictal/postictal 
severity (ictal/postictal), ten items. Each item was 
scored on a l-4-point Likert response scale. The reli- 
ability and validity of the scale was established prior 
to its use in a clinical tria16, and the responsiveness of 
the ictal/postictal scale was demonstrated in a double- 
blind crossover study of lamictal”. 
A number of limitations of the scale were identified 
from our previous work and these included problems 
with the comprehensiveness of the scale, its respon- 
siveness and the ability of the scale to cope with peo- 
ple with more than one seizure type. We have made 
a number of revisions to the scale. The objective of 
this study is to examine the psychometric properties 
of the revised seizure-severity scale. Further, to assess 
whether people with epilepsy could reliably differen- 
tiate between more than one seizure type and whether 
this would be reflected in subjects’ scores. 
MATERIALS AND METHODS 
Modifications to the scale 
Four items were added to improve the content validity 
of the scale. Additions to the ictal/postictal scale were 
whether patients smacked their lips, fidgeted or be- 
haved in an unusual way and whether they felt sleepy 
or not after a seizure. The percept scale additions were 
whether patients had seizures during the night or day 
and whether their seizures were clustered or not. The 
need to increase the responsiveness of the scale was 
addressed by adding a fifth response category to a 
four-items response choice for four of the items; the 
rationale for this was to make items more sensitive to 
the potential differences between simple and complex 
partial seizures and thus make the scale more respon- 
sive to potential treatment effects (e.g. the item about 
losing consciousness was revised to include a fifth 
response category: ‘No I have not blanked out or lost 
consciousness’). A fifth response category was also 
added to items 4, 10, 12 and 19 (see Table 1). 
Anecdotally a significant proportion of our patients 
were clearly able to describe the existence of two or 
Table 1: Contents of the Liveroool Seizure Severity Scale 
(adults) 
Percept subscale 
I Timing (specific or any time of the day)” 
2 Ability to predict seizures 
3 Ability to ‘fight off attacks 
4 Presence of an aurab 
5 Perceived control over attacks 
6 Clustering or random occurrencea 
7 Seizures in sleep only” 
8 Prevention of normal activities 
IctaVpostictal subscale 
9 Perceived overall severity 
IO Loss of consciousness 
I1 Degree of postictal confusion 
12 Duration of postictal confusionb 
I3 Failing to the ground 
I4 Postictal headache 
15 Postictal sleepiness 
I6 Incontinence 
17 Tongue biting 
18 Injury other than tongue-biting 
I9 Time to full recoveryb 
20 Lip smacking or fidgeting” 
a Additional items following revision. 
b Items where the scoring &tern has been expanded to include a 
fifth response. 
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even three types of seizures and they could differenti- 
ate them on the grounds of whether they were ‘major’ 
or ‘minor’ seizures. Therefore, it was decided that, as 
part of the further development of the scale, we would 
ask respondents who could identify both major and 
minor seizures to complete the scale: once about their 
minor seizures and one about their major seizures. 
We suggested that where patients could differentiate 
between two types of seizures that the most severe 
be referred to as the major seizure (being judged by 
whether or not they lost consciousness, duration of 
loss of consciousness, injury, time to recovery, and 
incontinence). The minor seizure, therefore, is that 
seizure which is the least severe. It is important to 
note that major and minor seizures do not refer to the 
Internation League Against Epilepsy (ILAE) classifi- 
cation. 
Subjects 
Ninety-seven patients with a clinical diagnosis of 
epilepsy uncomplicated by pseudoseizures and cur- 
rently taking antiepileptic medication were recruited 
consecutively from a specialist epilepsy clinic in the 
U.K. Patients were asked to complete the scale based 
on seizures they had experienced in the last 4 weeks. 
The possible scoring ranges are between 7 and 32 
for the percept scale and between 10 and 48 for the 
ictal/postictal scale. The higher the score the more 
severe the seizures. In addition to completing the 
seizure-severity scale for either one seizure type or 
both major and minor seizures, information was col- 
lected about their clinical and demographic details. 
Statistical methods 
The reliability of the scale was assessed in two ways: 
by examining the test-retest correlations and the in- 
ternal consistency alpha13. We hypothesized that pa- 
tients would be able to differentiate between their ma- 
jor and minor seizures and this would be reflected 
in their scores on the seizure-severity scale. Further 
evidence of the validity of the scale was sought by ’ 
examining the correlation between scores on the scale 
relating to both the major and minor seizures. 
RESULTS 
There were 97 patients (48 males and 49 females) 
who completed the scale. The mean age of the sam- 
ple was 32 years (range 15-70 years). Based on the 
ILEA classification of seizures 20% of respondents 
had simple partial seizures only, 60% complex par- 
tial seizures with or without secondary generalized 
seizures and 20% with primary generalized seizures 
only. 
Of the 97 respondents 32 of them reported that they 
had experienced more than one seizure type and were 
able to differently classify their seizures as either ‘ma- 
jor’ or ‘minor’. All 32 respondents completed their 
seizure-severity scale separately for both major and 
minor seizures. 
Reliability of the seizure-severity scale for major 
and minor seizures 
Assessment of the internal consistency of the scale 
was conducted on scales completed by all 97 re- 
spondents. Thirty of those 32 subjects with multiple- 
seizure types returned to the clinic to complete the 
seizure-severity scale a second time as part of the 
assessment of the test-retest reliability of the scale. 
The mean interval for the test-re-test was 14 days. 
None of the patients reassessed reported any signif- 
icant change in their seizure severity or frequency 
and none had had a change in medication during the 
intervening period. 
The internal consistency of the scale was 0.68 for 
the percept subscale and 0.86 for the ictal subscale 
when applied to major seizures, and 0.72 for the per- 
cept.and 0.78 for the ictal subscale when applied to 
minor seizures. Cronbach suggests that a score of 0.7 
and above is acceptable for both clinical and research 
purposes . I3 The test-retest scores (correlation coeffi- 
cients) for the scale for both major and minor seizures 
are as follows: major percept subscale p = 0.96, ma- 
jor ictal subscale p = 0.93, minor percept subscale 
p = 0.72, minor ictal subscale p = 0.78. Table 2 
presents the reliability scores for the original and re- 
vized seizure-severity scale. 
Criterion validity of the seizure-severity scale for 
major and minor seizures 
Respondents who completed the scale for both seizure 
types (n = 32) were able to differentiate between 
major and minor seizures on the revized seizure- 
severity scale for both the ictal/postictal scale and 
the percept scale. There was significant difference 
for the mean scores of the ictal/postictal subscale 
(t = 6.13, df = 35, p c 0.01) and the percept scales 
(t = 2.51, df = 35, p = 0.02) (see Table 3). 
DISCUSSION 
While a reduction in the frequency of seizures is 
an important outcome in the treatment of epilepsy, 
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Table 2: Range of scores for the Liverpool Seizure Severity Scale 
Item Variable 
Percept subscale 
1 Timing (specific or any time of day) 
2 Ability to predict seizures 
3 Ability to ‘fight off attacks 
4 Presence of an aura 
5 Perceived control over attacks 
6 Clustering or random occurrence 
1 Seizures in sleep only 
8 Prevention of normal activities 
Ictallpostictal subscale 
9 Perceived overall severity 
IO Loss of consciousness 
II Degree of postictal confusion 
I2 Duration of postictal confusion 
I3 Falling to the ground 
I4 Postictal headache 
I5 Postictal sleepiness 
I6 Incontinence 
‘1 Tongue biting 
I8 Injury other than tongue biting 
19 Time to full recovery 























2 3 4 
12.4 7.5 68 
I I.8 28.3 31.5 
4.6 30.6 57 
7.5 28.6 31.9 
28.3 19.6 35.2 
Il.6 42.5 32.1 
1.5 44.2 32.’ 
28.3 46.0 ‘6.5 
28.3 44.8 15.9 
14.1 21.’ 26.0 
29.5 25.1 12.4 
32.4 23.1 19.1 
13.0 21.2 3 I .5 
‘2.4 28.3 21.4 
16.5 22.9 12.1 
5.8 23. I 59.9 
8.4 ‘9.4 50.0 
5.8 41.2 43.4 
18.5 28.0 39.6 
IS.2 24.9 21.5 
Items I-4, 6, 1, 13-18 and 20: response categories; always, usually. sometimes, never. 
Item 5: response categories; very good, fairly good, little control, no control. 
Item 8: response categories: all of them, lot of them, few of them, none of them. 
Item 9: response categories; very severe, severe, mild, very mild. 
Item I I: response categories; very confused, fairly confused, slightly confused, not at all confused. 
Items IO and 12: response categories; cl min. l-2 min, 2-5 min. >5 min. 
Item 19: response categories; <I min. l-5 min. 6-60 min. >60 min. 
Table 3: ReliabiliW of the Liverpool Seizure Severity Scale 
Subscale Test-retest Internal consistency 
Adult version (orininal) 
Percept subscal; 0.19 0.69 
IctaVpostictal subscale 0.80 0.85 
Adult version (revised) 
Major seizures (N = 32) (N = 91) 
Percept subscale 0.96 0.62 
IctaVpostictal subscale 0.93 0.85 
Minor seizures (N = 32) (N = 91) 
Percept subscale 0.72 0.68 
IctaVpostictal subscale 0.18 0.86 
Table 4: Validity of the Liverpool Seizure Severity Scale 
(revised) 
Subscale Percept Ictal/postictal 
Seizure type Major Minor Major Minor 
Mean 15.53 14.56 30.11 23.78 
95% CI 14.58, 13.52, 28.00, 2 I .50. 
16.48 15.60 32.34 26.55 
other measures, including assessing the severity of 
seizures, also deserves consideration and have been 
the focus of recent research5*6.‘0.“. Current dissat- 
isfaction with counting seizures alone has been dis- 
cussed previously6 as have the merits of measuring 
patients’ perception of seizure severity9. 
We originally designed a 16-item, patient-based, 
seizure-severity scale that had good evidence of reli- 
ability and validity6 and sensitivity to change for the 
ictal/postictal scale 12, the latter being of crucial im- 
portance when such measures are used in clinical tri- 
als. Subsequent experience with the scale suggested 
that further development was necessary if the scale 
was to be accepted as a standard measure of efficacy 
for use in clinical trials. Consequently, four additional 
items were incorporated into the scale to improve 
its content validity. A fifth response category scoring 
zero has been added to three of the items to widen 
the gap between scores obtained for simple and com- 
plex partial seizures. These changes have the potential 
to improve detection of change attributable to drug 
treatment. The importance of catering for respondents 
with more than one seizure type was recognized. A 
simple method of asking respondents to differenti- 
ate between major and minor seizures now allows 
for them to complete the scale separately for each 
seizure type and monitor changes in their seizures 
where they have more than one seizure type. This 
approach, however, is only suitable for clinical trials 
where the different seizure types, as perceived by the 
patient, can be clarified with a trained investigator and 
could not be reliably used in postal questionnaires. 
Liverpool Seizure Severity Scale revisited 
The revised seizure-severity scale is both reliable 
and valid and maybe more sensitive to the effects of 
novel antiepileptic drug treatment. The percept is less 
likely to be amenable to change and therefore is not 
recommended for use in clinical drug trials. 
In conclusion, a valid measure of seizure severity 
is important if we are to fully understand the im- 
pact of novel AEDs in clinical trials. We have made 
a number of improvements to the Liverpool Seizure 
Severity Scale in order to enhance its reliability, va- 
lidity and responsiveness. Further evidence of the va- 
lidity and responsiveness of the scale is necessary if 
it is to be acceptable as a standardized measure of 
seizure severity in clinical trials. The utility of the 
revised seizure-severity scale is being evaluated in 
add-on trials of remacemide, tiagabine, lamotrigine 
and topirimate. The seizure-severity scale has been 
translated into several different languages using for- 
ward and backward translation technique. A child’s 
version of the scale has also been developed14. Fi- 
nally, the seizure-severity scale forms an integral part 
of a health-related quality of life measure”, within 
which the aim is not to provide an alternative mea- 
sure to seizure frequency but a complimentary one 
which will enhance our understanding of the impact 
of epilepsy and its treatment. 
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